Comparing the high-dose dexamethasone effect versus prednisolone in treatment of immune thrombocytopenic purpura patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211111053039N1

Enrollment

Registered

2022-01-24

Start date

2021-11-06

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune thrombocytopenic purpura.

Interventions

Intervention 1: Intervention group: dexamethasone intravenous 40 mg daily to 4 days. Intervention 2: Intervention group: edible prednisolone of 1 mg/kg body weight daily.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with ITP, which are newly diagnosed and have been treated and previously no therapies

Exclusion criteria

Exclusion criteria: People with life-threatening bleeding such as brain hemorrhage People with trauma People who have recent surgery

Design outcomes

Primary

Measure	Time frame
Platelets count. Timepoint: daily. Method of measurement: complete blood count.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Zahmatyar

Oroumia University of Medical Sciences

zahmatyar.f@gmail.com+98 44 3346 9856

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026